Literature DB >> 17760529

Cognitive dysfunction in cancer patients: an educational needs area improved by a single intervention.

Irene Perez Vetto1, John T Vetto.   

Abstract

BACKGROUND: Chemotherapy-related cognitive dysfunction (CRCD) is increasingly recognized as an important cause of posttreatment morbidity, with significant impact on quality of life. We sought to evaluate the level of need for and awareness of information regarding CRCD among nurses involved with the care of persons receiving chemotherapy. We also hypothesized that educational interventions are useful in this increasingly important area of oncology nursing.
METHODS: Chemotherapy nurse providers were surveyed regarding CRCD beliefs and skills; a subset of individuals attending a CRCD educational session underwent pretesting and posttesting to assess CRCD knowledge.
RESULTS: Respondents perceived that CRCD is a serious problem and identified the following needs areas: general CRCD education, diagnostic skills, knowledge regarding behavioral and pharmacologic interventions, and availability of adequate CRCD practice protocols. With a single educational intervention, posttest scoring improved over pretest in most subjects, with a statistically significant overall improvement in mean scores.
CONCLUSIONS: Our results suggest the need for education in CRCD diagnosis, intervention, and protocol development. A single educational intervention improved knowledge. Our work underscores the importance of CRCD education for the Oncology Education Services and other oncology nurse educational resources.

Entities:  

Mesh:

Year:  2007        PMID: 17760529     DOI: 10.1007/bf03174337

Source DB:  PubMed          Journal:  J Cancer Educ        ISSN: 0885-8195            Impact factor:   2.037


  14 in total

1.  Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen.

Authors:  Steven A Castellon; Patricia A Ganz; Julienne E Bower; Laura Petersen; Laura Abraham; Gail A Greendale
Journal:  J Clin Exp Neuropsychol       Date:  2004-10       Impact factor: 2.475

Review 2.  Homocysteine and cognitive function.

Authors:  Aron Troen; Irwin Rosenberg
Journal:  Semin Vasc Med       Date:  2005-05

Review 3.  Phosphodiesterase inhibitors for cognitive enhancement.

Authors:  Gregory M Rose; Allen Hopper; Michael De Vivo; Ashok Tehim
Journal:  Curr Pharm Des       Date:  2005       Impact factor: 3.116

4.  Electrophysiological correlates of information processing in breast-cancer patients treated with adjuvant chemotherapy.

Authors:  Baudewijntje P C Kreukels; Sanne B Schagen; K Richard Ridderinkhof; Willem Boogerd; Hans L Hamburger; Frits S A M van Dam
Journal:  Breast Cancer Res Treat       Date:  2005-11       Impact factor: 4.872

5.  Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome.

Authors:  Christina A Meyers; Maher Albitar; Elihu Estey
Journal:  Cancer       Date:  2005-08-15       Impact factor: 6.860

Review 6.  Side-effects of chemotherapy and quality of life in ovarian and breast cancer patients.

Authors:  Anne E Kayl; Christina A Meyers
Journal:  Curr Opin Obstet Gynecol       Date:  2006-02       Impact factor: 1.927

Review 7.  Chemotherapy-induced cognitive dysfunction: a clearer picture.

Authors:  Joyce A O'Shaughnessy
Journal:  Clin Breast Cancer       Date:  2003-11       Impact factor: 3.225

Review 8.  Chemotherapy-related cognitive dysfunction in breast cancer.

Authors:  Joyce O'Shaughnessy
Journal:  Semin Oncol Nurs       Date:  2003-11       Impact factor: 2.315

9.  Cognitive function, fatigue, and menopausal symptoms in breast cancer patients receiving adjuvant chemotherapy: evaluation with patient interview after formal assessment.

Authors:  Fiona P Downie; Helen G Mar Fan; Nadine Houédé-Tchen; Qilong Yi; Ian F Tannock
Journal:  Psychooncology       Date:  2006-10       Impact factor: 3.894

10.  The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial.

Authors:  Jeffrey S Wefel; Renato Lenzi; Richard L Theriault; Robert N Davis; Christina A Meyers
Journal:  Cancer       Date:  2004-06-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.